Abstract Body

Background:

Acquisition of HCV is frequent among people with HIV (PWHIV), an event that profoundly modifies the natural history of both infections. Our goal was to analyze whether HCV clearance by direct-acting antivirals (DAAs) after chronic infection can partially restore both molecular and cellular immune profile to levels similar to those found in PWHIV. In addition, we explored whether changes over time in these patients were similar to those found in patients who cleared HCV spontaneously after acute infection.

Methods:

We performed a longitudinal observational study in 88 PWHIV: i) 31 with active chronic HCV infection (CHC) prior to starting DAA therapy and 48 weeks after achieving sustained virological response (SVR); ii) 25 who previously cleared HCV spontaneously (AE); iii) 32 controls (HIV) never infected with HCV. Both AE and HIV also were follow-up 48 weeks after first sample. A total of 27 CD4+ and CD8+ peripheral T cell subsets were assessed by spectral flow cytometry (18 antibodies) as well as 73 plasma molecules by multiplex immunoassay (Luminex, procartaplex). Differences in cell populations and plasma molecules were assessed by generalized linear models adjusted for the most significant clinical variables and multiple comparisons (p-value corrected by Benjamin-Hochberg (q<0.15).

Results:

At follow-up, lower levels of senescence markers (PD1, CD57) and central memory (CD3+CD4+or CD8+CD45RA-CCR7+CD27+CD28+) and naïve (CD3+CD4+or CD8+CD45RA+CCR7+CD27+CD28+) CD4+ and CD8+ T cells were observed in the CHC group compared to control. On the other hand, the AE group showed an increase in exhausted immune cells and immunosenescence markers over time to levels similar to those of HIV+ control patients. Also, AE group showed a higher level of effector memory CD4+ and CD8+ T cells (EM:CD45RA-CCR7-; EM_TH01: CD45RA-CCR7-CD28+CD27+; EM_TH1: CD45RA-CCR7-CD28-CD27-; EM _TH12: CD45RA-CCR7-CD28+CD27-) than HIV. The immune profile of the CHC and AE groups were very similar at follow-up. Regarding plasma molecules, 48 weeks after achieving SVR, a decrease in proinflammatory cytokines, checkpoint inhibitors and immune cell activation was observed compared to values before initiation of DAAs therapy.

Conclusions:

Clearance with DAAs after chronic HCV infection improved cellular senescence profile but remained higher than controls. The slightly higher levels of circulating immunosenescence markers after 1-year follow-up in the AE group may indicate possible accelerated aging driven by acute HCV infection.